U.S. Markets closed
  • S&P 500

    4,432.99
    -40.76 (-0.91%)
     
  • Dow 30

    34,584.88
    -166.44 (-0.48%)
     
  • Nasdaq

    15,043.97
    -137.96 (-0.91%)
     
  • Russell 2000

    2,236.86
    +3.95 (+0.18%)
     
  • Crude Oil

    71.98
    -0.63 (-0.87%)
     
  • Gold

    1,752.00
    -4.70 (-0.27%)
     
  • Silver

    22.42
    -0.33 (-1.44%)
     
  • EUR/USD

    1.1733
    -0.0039 (-0.3285%)
     
  • 10-Yr Bond

    1.3700
    +0.0390 (+2.93%)
     
  • Vix

    21.25
    +2.56 (+13.70%)
     
  • GBP/USD

    1.3734
    -0.0063 (-0.4546%)
     
  • USD/JPY

    109.9600
    +0.2420 (+0.2206%)
     
  • BTC-USD

    47,392.60
    -143.42 (-0.30%)
     
  • CMC Crypto 200

    1,199.39
    -26.14 (-2.13%)
     
  • FTSE 100

    6,963.64
    -63.84 (-0.91%)
     
  • Nikkei 225

    30,500.05
    +176.71 (+0.58%)
     

SHAREHOLDER ALERT: Robbins LLP Reminds Investors that Ardelyx Inc. (ARDX) is Being Sued for Misleading Shareholders

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

SAN DIEGO, CA / ACCESSWIRE / August 30, 2021 / Shareholder rights law firm Robbins LLP reminds investors that a class action has been filed on behalf of all purchasers of Ardelyx Inc. securities (NASDAQ: ARDX) between August 6, 2020 and July 19, 2021, for violations of the Securities Exchange Act of 1934. Ardelyx is a biopharmaceutical company that develops medicines for people with cardiorenal disease. Ardelyx's lead drug candidate is tenapanor, a medicine for the control of serum phosphorus in adult patients with chronic kidney disease on dialysis.

If you suffered a loss due to Ardelyx Inc.'s misconduct, click here.

Ardelyx Inc. (ARDX) Made Misleading Statements in its Registration Statement in Connection with its Initial Public Offering
According to the complaint, defendants submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for tenapanor in June 2020. The FDA accepted the NDA in September 2020 and set a Prescription Drug User Fee Act date of April 29, 2021. During the relevant period, the Company touted the efficacy of tenapanor and its "positive" clinical trial results that showed "improvements" over current treatments and reinforced its "potential" as a "transformative" treatment. Then, on July 19, 2021, Ardelyx announced that it had received a letter from the FDA, dated July 13, 2021, that said the FDA detected issues with both the size and clinical relevance of the drug's treatment effect. On this news, analysts cut their price targets and downgrade the Company's rating. Ardelyx's share price fell 74% in one day, to close at $2.01 per share on July 20, 2021, before falling again on July 21, 2021. The stock has yet to recover.

If you purchased shares of Ardelyx Inc. (ARDX) between August 6, 2020 and July 19, 2021, you have until September 28, 2021, to ask the court to appoint you lead plaintiff for the class.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

Contact us to learn more:
Lauren Levi
(800) 350-6003
llevi@robbinsllp.com
Shareholder Information Form

Robbins LLP is a nationally recognized leader in shareholder rights law. To be notified if a class action against Ardelyx Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

CONTACT:
Lauren Levi
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
llevi@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

SOURCE: Robbins LLP



View source version on accesswire.com:
https://www.accesswire.com/662094/SHAREHOLDER-ALERT-Robbins-LLP-Reminds-Investors-that-Ardelyx-Inc-ARDX-is-Being-Sued-for-Misleading-Shareholders